Download
s00432-021-03599-2.pdf 524,10KB
WeightNameValue
1000 Titel
  • Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2− breast cancer resistant to endocrine therapy: VinoMetro—AGO-B-046
1000 Autor/in
  1. Krajnak, Slavomir |
  2. Decker, Thomas |
  3. Schollenberger, Lukas |
  4. Rosé, Christian |
  5. Ruckes, Christian |
  6. Fehm, Tanja |
  7. Thomssen, Christoph |
  8. Harbeck, Nadia |
  9. Schmidt, Marcus |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-03-20
1000 Erschienen in
1000 Quellenangabe
  • 147(11):3391-3400
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00432-021-03599-2 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484172/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!Metronomic chemotherapy (MCT) is an increasingly used treatment option in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced/metastatic breast cancer (MBC) after failure of endocrine-based therapies.!##!Methods!#!VinoMetro was a multicentre, open-label, single-arm, phase II study of metronomic oral vinorelbine (VRL; 30 mg/day) as a first-line chemotherapy (CT) in patients with HR+/HER2- MBC after endocrine failure. The primary endpoint was the clinical benefit rate (CBR) at 24 weeks.!##!Results!#!Between January 2017 and April 2019, nine patients were enrolled. The CBR was 22.2% (90% confidence interval [CI] 4.1-55.0), p = 0.211. The median progression-free survival (PFS) was 12.0 weeks (95% CI 11.3-12.7). Grade 3-4 adverse events (AEs) occurred in 22.2% of patients. One patient died of febrile neutropenia.!##!Conclusion!#!VinoMetro (AGO-B-046) was closed early after nine patients and occurrence of one grade 5 toxicity in agreement with the lead institutional review board (IRB). Metronomic dosing of oral VRL in HR+/HER2- MBC as first-line CT after failure of endocrine therapies showed only limited benefit in this population.!##!Trial registration number and date of registration!#!ClinicalTrials.gov Identifier: NCT03007992; December 15, 2016.
1000 Sacherschließung
lokal Female [MeSH]
lokal Daily oral vinorelbine
lokal Metastatic breast cancer
lokal Aged [MeSH]
lokal Original Article – Clinical Oncology
lokal Receptor, ErbB-2/metabolism [MeSH]
lokal Humans [MeSH]
lokal Neoplasm Metastasis [MeSH]
lokal Progression-Free Survival [MeSH]
lokal Breast Neoplasms/drug therapy [MeSH]
lokal Breast Neoplasms/metabolism [MeSH]
lokal Middle Aged [MeSH]
lokal Administration, Metronomic [MeSH]
lokal Administration, Oral [MeSH]
lokal Clinical benefit rate
lokal Neoplasm Staging [MeSH]
lokal Receptors, Estrogen [MeSH]
lokal Receptors, Steroid/metabolism [MeSH]
lokal Metronomic chemotherapy
lokal Vinorelbine/administration
lokal Breast Neoplasms/pathology [MeSH]
lokal Antineoplastic Agents, Phytogenic/administration
lokal Drug Resistance, Neoplasm [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/S3Jham5haywgU2xhdm9taXI=|https://frl.publisso.de/adhoc/uri/RGVja2VyLCBUaG9tYXM=|https://frl.publisso.de/adhoc/uri/U2Nob2xsZW5iZXJnZXIsIEx1a2Fz|https://frl.publisso.de/adhoc/uri/Um9zw6ksIENocmlzdGlhbg==|https://frl.publisso.de/adhoc/uri/UnVja2VzLCBDaHJpc3RpYW4=|https://frl.publisso.de/adhoc/uri/RmVobSwgVGFuamE=|https://frl.publisso.de/adhoc/uri/VGhvbXNzZW4sIENocmlzdG9waA==|https://frl.publisso.de/adhoc/uri/SGFyYmVjaywgTmFkaWE=|https://orcid.org/0000-0003-1365-2414
1000 Hinweis
  • DeepGreen-ID: 8ba98412eb274ef08b75b69128daf9ed ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6449892.rdf
1000 Erstellt am 2023-05-09T10:30:35.249+0200
1000 Erstellt von 322
1000 beschreibt frl:6449892
1000 Zuletzt bearbeitet 2023-10-21T02:12:24.775+0200
1000 Objekt bearb. Sat Oct 21 02:12:24 CEST 2023
1000 Vgl. frl:6449892
1000 Oai Id
  1. oai:frl.publisso.de:frl:6449892 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source